Myasthenia Gravis Study (H-28126)
Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles. MG is caused by a defect in the transmission of nerve impulses to muscles. It occurs when normal communication between the nerve and muscle is interrupted at the neuromuscular junction, which is the place where nerve cells connect with the muscles they control. The purpose of this study is to test the effectiveness and safety of an experimental drug. This investigational drug may partially improve muscle strength in patients with MG.